1. Academic Validation
  2. Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics

Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics

  • Sci Rep. 2022 May 3;12(1):7154. doi: 10.1038/s41598-022-11189-6.
Pooja Dasgupta 1 Anika Mann 1 Willma E Polgar 2 Rainer K Reinscheid 1 Nurulain T Zaveri 2 Stefan Schulz 3
Affiliations

Affiliations

  • 1 Department of Pharmacology and Toxicology, Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University, Drackendorfer Straße 1, 07747, Jena, Germany.
  • 2 Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, CA, 94043, USA.
  • 3 Department of Pharmacology and Toxicology, Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University, Drackendorfer Straße 1, 07747, Jena, Germany. Stefan.Schulz@med.uni-jena.de.
Abstract

Multi-receptor targeting has been proposed as a promising strategy for the development of opioid analgesics with fewer side effects. Cebranopadol and AT-121 are prototypical bifunctional ligands targeting the nociceptin/orphanin FQ peptide receptor (NOP) and µ-opioid receptor (MOP) that elicit potent analgesia in humans and nonhuman primates, respectively. Cebranopadol was reported to produce typical MOP-related side effects such as respiratory depression and reward, whereas AT-121 appeared to be devoid of these liabilities. However, the molecular basis underlying different side effect profiles in opioid analgesics remains unknown. Here, we examine agonist-induced receptor phosphorylation and G protein signaling profiles of a series of chemically diverse mixed MOP/NOP agonists, including cebranopadol and AT-121. We found that these compounds produce strikingly different MOP phosphorylation profiles. Cebranopadol, AT-034 and AT-324 stimulated extensive MOP phosphorylation, whereas AT-201 induced selective phosphorylation at S375 only. AT-121, on the other hand, did not promote any detectable MOP phosphorylation. Conversely, none of these compounds was able to elicit strong NOP phosphorylation and low NOP receptor phosphorylation correlated with partial agonism in a GIRK-channel assay. Our results suggest a close correlation between MOP receptor phosphorylation and side effect profile. Thus, bifunctional MOP/NOP opioid ligands combining low efficacy G protein signaling at both NOP and MOP with no detectable receptor phosphorylation appear to be devoid of side-effects such as respiratory depression, abuse liability or tolerance development, as with AT-121.

Figures
Products